- Home
- RIV vs CMPX Comparison
RIV vs CMPX Comparison
Compare RIV & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- CMPX
- Stock Information
- Founded
- RIV 2015
- CMPX 2014
- Country
- RIV United States
- CMPX United States
- Employees
- RIV N/A
- CMPX N/A
- Industry
- RIV Finance Companies
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- RIV Finance
- CMPX Health Care
- Exchange
- RIV Nasdaq
- CMPX Nasdaq
- Market Cap
- RIV 254.6M
- CMPX 214.6M
- IPO Year
- RIV N/A
- CMPX N/A
- Fundamental
- Price
- RIV $12.22
- CMPX $2.60
- Analyst Decision
- RIV
- CMPX Strong Buy
- Analyst Count
- RIV 0
- CMPX 4
- Target Price
- RIV N/A
- CMPX $13.75
- AVG Volume (30 Days)
- RIV 87.6K
- CMPX 2.2M
- Earning Date
- RIV 01-01-0001
- CMPX 11-12-2024
- Dividend Yield
- RIV 12.85%
- CMPX N/A
- EPS Growth
- RIV N/A
- CMPX N/A
- EPS
- RIV N/A
- CMPX N/A
- Revenue
- RIV N/A
- CMPX $850,000.00
- Revenue This Year
- RIV N/A
- CMPX N/A
- Revenue Next Year
- RIV N/A
- CMPX $613.39
- P/E Ratio
- RIV N/A
- CMPX N/A
- Revenue Growth
- RIV N/A
- CMPX N/A
- 52 Week Low
- RIV $9.63
- CMPX $0.77
- 52 Week High
- RIV $12.43
- CMPX $2.70
- Technical
- Relative Strength Index (RSI)
- RIV 57.45
- CMPX 76.97
- Support Level
- RIV $11.77
- CMPX $1.43
- Resistance Level
- RIV $12.15
- CMPX $2.70
- Average True Range (ATR)
- RIV 0.21
- CMPX 0.29
- MACD
- RIV 0.07
- CMPX 0.12
- Stochastic Oscillator
- RIV 100.00
- CMPX 92.31
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.